Press release
Alzheimer's Drugs Market - Technological Advancements, Evolving Industry Trends and Insights by 2018
The research report on the Alzheimer’s drugs market provides a comprehensive snapshot of the trends, growth drivers and restraints that will influence the market over the forecast period 2012 to 2018. The report analyzes these shifting dynamics to come up with accurate projections for the market in the coming years. Our analysts lay emphasis on factors such as: recent technological developments, competitive mapping, analysis using Porter’s five forces model, and company profiles for insight into the financial standing, product pipelines and new initiatives of players in the Alzheimer’s drugs market.Download Exclusive Sample of this Report: http://bit.ly/2gAw4eH
This report also takes into account the macro and micro aspects of this market that will influence business-related decisions pertaining to Alzheimer’s drugs. It enumerates the factors that will prove essential for the sustenance and growth of enterprises in the global Alzheimer’s drugs market. Further, by studying the value chain and market structure in depth, the report gives businesses unmatched visibility into the opportunities that can be effectively monetized in the Alzheimer’s drugs market. By studying market projections for the years until 2018, this report is able to provide estimates that supplement prudent investments in the Alzheimer’s drugs market.
Alzheimer’s disease is classified as a progressive neurological disease that affects the functioning of the brain, ultimately leading to neuron loss. The combined effects of this neurological degradation are: the loss of reasoning abilities and memory.
Currently, the market offers no definitive treatment to prevent or cure Alzheimer’s disease – the only result currently offered by Alzheimer’s drugs is to curtail the progression of the disease. Patients of Alzheimer’s are usually prescribed neurotransmitters such as memantine and cholinesterase inhibitors. These drugs work by slowing down the progression of Alzheimer’s disease. They also provide temporary relief from common Alzheimer’s symptoms such as anxiety, depression, and insomnia, as well as agitation in some instances.
A method to provide early diagnosis of Alzheimer’s is not yet available - but there is a pressing demand on market players to offer techniques that enable the early detection of Alzheimer’s.
The estimates of this report show that the global Alzheimer’s drugs market will show sluggish growth over the forecast period. The growth will mainly slow down owing to a lack of techniques for diagnosing or treating Alzheimer’s disease.
Until now, the most dominant geographical region in the Alzheimer’s drugs market was North America, as it occupied 50% of market shares. While it will continue to hold its leading position, it will be overtaken – in terms of growth rate – by emerging economies such as Russia, India, China, and Australia as these regions experience high unmet medical needs.
The growing geriatric population is yet another reason that will impel growth in the global Alzheimer’s drugs market, making it imperative for players to launch new drugs and treatments. Many market players are now focusing on research and development centric activities, which could potentially result in breakthroughs. At the same time, the global Alzheimer’s drugs market will have to contend with challenges such as drug patent expiry.
Browse Research Report: http://bit.ly/2fo7nNn
Leading market participants that have been profiled in the Alzheimer’s drugs market research report are: Pfizer Incorporated, Forest Laboratories, Inc., Eisai Co., Ltd., Novartis AG, and H. Lundbeck A/S.
About Us
Transparency Market Research (TMR) is a global market intelligence company providing business information reports and services. The company’s exclusive blend of quantitative forecasting and trend analysis provides forward-looking insight for thousands of decision makers. TMR’s experienced team of analysts, researchers, and consultants use proprietary data sources and various tools and techniques to gather and analyze information.
TMR’s data repository is continuously updated and revised by a team of research experts so that it always reflects the latest trends and information. With extensive research and analysis capabilities, Transparency Market Research employs rigorous primary and secondary research techniques to develop distinctive data sets and research material for business reports.
Contact Us
Transparency Market Research
State Tower,
90 State Street, Suite 700
Albany, NY 12207
United States
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453
Email: sales@transparencymarketresearch.com
Website: http://www.transparencymarketresearch.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Alzheimer's Drugs Market - Technological Advancements, Evolving Industry Trends and Insights by 2018 here
News-ID: 386185 • Views: …
More Releases from TMR - Research Reports

Pulmonary Drugs Market is Expected to Reach US$ 28,082.1 Million by the End of 2 …
According to the research report, the global pulmonary drugs market is expected to be worth US$ 28,082.1 mn by the end of 2024 as compared to US$ 48,039.7 mn in 2015. Analysts calculate that the global market will plummet at a CAGR of -6.3% during the forecast period of 2016 and 2024. The market will thrive as the demand for combination drugs is anticipated to remain on the rise during…

North America Ventricular Assist Device Market is rising to a valuation of US$ 1 …
According to TMR, the opportunity in the North America market for VADs, which stood at US$0.4 bn in 2015, is likely to expand at a healthy CAGR of 9.20% between 2016 and 2024 and increase to US$1.07 bn by the end of the forecast period. The destination therapy (DT) segment has been reporting a greater application of VADs than the other two indication segments. It is expected to remain the…

Dental Membrane and Bone Graft Substitutes Market to rise to US$ 922.6 Million b …
Transparency Market Research notes that innovation and expansion into emerging regions have served these companies well in strengthening their hold in the dental membrane and bone graft substitutes market. For instance, Switzerland-based Geistlich Pharma AG - a global manufacturer and supplier of dental products and devices - expanded its operations in Sydney, Australia and New Delhi, India in 2016.
The global dental membrane and bone graft substitutes market is expected to…

Human Vaccines Market is Estimated to Reach US$ 72.5 Billion by 2024
The global human vaccines market was valued at US$28.3 bn in 2015 and is estimated to reach US$72.5 bn by 2024, registering an 11.2% CAGR during the forecast period.
By age group, pediatric vaccines accounted for a 57.5% share in the global human vaccines market in 2015. Adult vaccines, on the other hand, are expected to expand at a 13.2% CAGR from 2016 to 2024. Based on product, the pneumococcal segment…
More Releases for Alzheimer’s
Europe Alzheimer’s Drug Pipeline Analysis
The incidence of Alzheimer’s disease has been on a rise in Europe in recent years and it most likely to continue rising in the near future. It has been observed that close to 50% of dependency of aged people in Europe is attributed for by Alzheimer’s disease. The rapid growth in the prevalence of Alzheimer's disease over the next few decades in Europe is expected to result in immense pressure…
Media Advisory: Alzheimer’s Disease Resource Center, Inc. Presents 10th Annual …
Who: Mary Ann Malack-Ragona, Executive Director/Chief Executive Officer, Alzheimer’s Disease Resource Center, Inc. (ADRC)
Participating Walk for Alzheimer’s teams and individuals
Mickey B, Radio Personality, WGBB Radio and Master of Ceremonies
Ronald McDonald
The Liberty Bells, USO troupe
What: Alzheimer’s Disease Resource Center, Inc. (ADRC) is presenting its 10th Annual Old Bethpage Walk for Alzheimer’s & Mexican Fiesta. There will be an opening ceremony with Mickey B, Radio Personality, WGBB Radio, as the Master of…
Home Care Assistance Partners with the Alzheimer’s Association to Promote Earl …
(Palo Alto, CA – November 29, 2011) Home Care Assistance, North America’s leading provider of in-home care for seniors, announced today that, along with companies including Genworth, Starbucks, Intel and Pfizer, they are now a Champion Partner of the Alzheimer’s Early Detection Alliance (AEDA). The AEDA is a program renowned for raising Alzheimer’s awareness and promoting early detection of the disease. As a member of this important alliance, Home…
Alzheimer’s Association Long Island Announces Release of Latest Report on Alzh …
Alzheimer’s Association Long Island announced the release of the most recent report about Alzheimer’s disease. “Alzheimer’s from the Frontlines: Challenges a National Alzheimer’s Plan Must Address” provides a look into the unrelenting challenges brought on by this disease by offering insights and perspectives from individuals across the country who participated in the Alzheimer’s Association’s public input process. The Association and over 70 of its chapters hosted 132 input sessions throughout…
Otava Alzheimer’s Disease Targeted Libraries
Alzheimer’s disease (AD) is a devastating and always fatal neurodegenerative disorder characterized by progressive impairment of cognitive function and emotional disturbances. Currently, more than 25 million people worldwide live with AD. But there is no cure for AD and no treatment to reverse its progression, there are medicines available that can help treat symptoms in some people with this disease. Intensive scientific research around the world brings us closer to…
Alzheimer’s Association Long Island Presents Public Input Session for National …
On August 24, Alzheimer’s Association Long Island will hold a public input session to solicit views, comments and perspectives from stakeholders in the Alzheimer’s community to assist in the development of a successful National Alzheimer’s Plan. The recommendations and comments expressed during these input sessions, taking place across the country in August, will be collected and shared this fall with officials from the U.S. Department of Health and Human Services,…